Personalised cancer immunotherapy company BreakBio Corp announced on Monday that it is entering the clinic next quarter.

BreakBio says it is designed for higher efficacy than Moderna's individualised neoantigen therapy (INT). For every patient, its platform integrates tumour DNA sequencing, RNA sequencing, and mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient's cancer cells.

Unlike approaches focused only on mutation-related neoantigen targets found in high-mutational cancers like melanoma, BreakBio targets neoantigens and also targets non-mutated antigens (found by its AI platform per patient) in order to broaden the treatment to all solid tumours.